Halozyme Therapeutics — Aug 6, 2026 release

For the full year 2026, the Company expects: • Total revenue of $1.835 billion to $1.910 billion, representing growth of 31% to 37% over 2025 total revenue, primarily driven by increases in royalty revenue and product sales from API. • Revenue from royalties of $1.220 billion to $1.245 billion, representing growth of 41% to 43% over 2025. • Adjusted EBITDA of $1.225 billion to $1.280 billion, representing growth of 86% to 95% over 2025, including new Hypercon™ and Surf Bio investments of approximately $60 million. • Non-GAAP diluted earnings per share of $8.65 to $9.00, representing growth of 108% to 117% over 2025. The Company’s earnings per share guidance includes new Hypercon™ and Surf Bio investments of approximately $60 million and does not consider the impact of potential future share repurchases. Table 1. 2026 Financial Guidance Previous Guidance Range New Guidance Range Total Revenue $1.710 to $1.810 billion $1.835 to $1.910 billion Royalty Revenue $1.130 to $1.170 billion $1.220 to $1.245 billion Adjusted EBITDA 1 $1.125 to $1.205 billion $1.225 to $1.280 billion Non-GAAP Diluted EPS 1 $7.75 to $8.25 $8.65 to $9.00 1     EBITDA, Adjusted EBITDA and Non-GAAP Diluted EPS are Non-GAAP financial measures. See “Note Regarding Use of Non-GAAP Financial Measures” below for an explanation of these measures. Reconciliations between GAAP reported and Non-GAAP financial information for actual results are provided at the end of this earnings release. Webcast and Conference Call Halozyme will host its Quarterly Update Conference Call for the second quarter ended June 30,